Related Experiment Video

Updated: Jun 3, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

A M Martelli1, C Evangelisti, W Chappell

  • 1Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore, Università di Bologna, Bologna, Italy.

Leukemia
|March 26, 2011
PubMed

Insights

Protein translation regulation is key in controlling cell growth and leukemia. Targeting the PI3K/PTEN/Akt/mTOR pathway, especially with novel kinase inhibitors, may offer more effective leukemia therapies.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Signaling

Background:

  • Protein translation regulation is crucial for cell growth and leukemic transformation.
  • The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in cancer, impacting therapy response.
  • PTEN, a tumor suppressor, is often altered in cancer, leading to Akt activation and uncontrolled cell growth.

Purpose of the Study:

  • To investigate the role of the PI3K/PTEN/Akt/mTOR pathway in controlling cell growth and leukemic transformation.
  • To explore the therapeutic potential of targeting this pathway in leukemia.

Main Methods:

  • Analysis of dysregulated signaling in the PI3K/PTEN/Akt/mTOR pathway.
  • Investigation of PTEN alterations (mutation, silencing, haploinsufficiency).
  • Study of mTOR Complex 1 (mTORC1) regulation of mRNA translation, specifically for growth-related mRNAs with long 5'-untranslated regions.

Main Results:

  • Dysregulation of the PI3K/PTEN/Akt/mTOR pathway, through genetic alterations or autocrine mechanisms, drives leukemic transformation.
  • mTORC1 activity, enhanced by upstream signaling, promotes translation of critical mRNAs for cell growth and survival via 4E-BP1 phosphorylation.
  • Rapamycin and rapalogs show cytostatic effects, but novel inhibitors targeting PI3K and mTOR kinase activity may be more effective.

Conclusions:

  • The PI3K/PTEN/Akt/mTOR pathway is a critical regulator of cell growth and leukemia development.
  • Targeting mTORC1 is a viable strategy, with novel kinase inhibitors showing promise for more potent anti-leukemic effects than current therapies.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: